Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
about
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent associationInhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domainOncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gammaA case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancerAberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast CancerInsights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesConstitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasiaThe erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potencyA putative molecular-activation switch in the transmembrane domain of erbB2.Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.A subdomain in the transmembrane domain is necessary for p185neu* activation.Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancerHER2/neu: mechanisms of dimerization/oligomerization.Targeting HER2 in breast cancer: overview of long-term experienceThe oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisRole of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.Targeting the function of the HER2 oncogene in human cancer therapeutics.Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis.Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growthExpression of growth factor receptors in human brain tumours.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerTransmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.The juxtamembrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction.The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activityTransformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene.Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.Multiple cis- and trans-acting elements involved in regulation of the neu gene.A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency.Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domainsTransmembrane helix-helix interactions involved in ErbB receptor signaling.Pharmacogenetics and breast cancer management: current status and perspectives.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.her-2 upstream open reading frame effects on the use of downstream initiation codons.Specificity and promiscuity in membrane helix interactions.The significance of heregulin in breast cancer tumor progression and drug resistance.
P2860
Q24297029-BB6CB309-3D8A-4A9B-BC34-FA366896E91CQ24551173-B2614743-1BD2-460D-98A6-DFB7103014C4Q24561375-6CD4FA4E-1F13-4825-A900-1134458CC1E1Q24810260-47C8CDED-923C-417F-9BA1-37B417F9B20CQ26773907-A9605DDD-051F-49CC-81CF-94D8A32C62B5Q27683825-A53B9B88-63CF-4766-A6BE-53112885A507Q28640044-2FF25132-9136-4681-9976-F06ECFF68FC1Q28678671-9B1DD41D-73F7-4119-A705-A72A4C690C9CQ30476898-0CF60335-F35E-4799-B3C4-0DA100CCC977Q30837688-CC17705C-A372-4A80-A3AF-66A07D70D7E2Q33937484-9A1FDA29-D7AF-47D6-912E-E240E9C5C3C5Q33967189-A95D6485-5B85-49D2-BF4B-DF4B98DC4935Q34130541-3B4DDA81-3D66-4EE6-B0C3-BF960BFB59F7Q34272044-B9C0F149-9716-434D-BAB3-6AA2255258CCQ34493341-581C0DDC-7DD3-44BE-94D1-208BE5E50FA8Q34525985-C78DA926-1426-460E-A5D4-EEE002422461Q34766486-53A2CA5A-E196-4997-94F1-0F8A027FAF31Q34872708-9B239011-9C47-4216-96D5-963B3EEF1EF5Q35686940-4AD059E6-CF32-4684-A0C2-73B4ECAB4AE1Q35699888-61586F6B-452D-4FEE-845C-68A47C60CCAAQ35977584-61A5535C-13E6-4641-B4D3-4210AA6B2AF6Q35982942-258676CC-962B-43BD-9260-8006D3073572Q36064912-40C6351D-068B-4449-8520-82F211E30E9EQ36274097-31CCAD76-3E18-4CD1-BE7B-80A0F4395855Q36696910-AC946BE9-BE9F-43C5-AF90-080C08B620CAQ36710439-BBB12F47-D663-49A2-930F-AA00C73996E5Q36712215-C469CC0A-E621-432C-8B3F-B3BFB5BF3BD9Q36719220-B8FDF992-92D4-4366-81BC-4A4CC313BE7EQ36774310-8B2E6F35-A711-44AD-BC87-47E975C85917Q37054957-239C780F-3B1D-4722-9107-D0837C583095Q37218987-6EC7385E-4982-477C-A8D8-635AACEEA6E2Q37360070-BC635E95-4EB7-438A-9652-D74914101585Q37511109-5C4B993C-B7E8-45DF-8779-8045580934B1Q37704902-FE083E22-C068-4060-9C88-AC1249106356Q38358816-A24E3A26-4995-4E28-A82D-6C6BB30873DEQ38673589-5F6632AD-71D8-427B-9D5F-A612656F91D4Q39675983-54F4799D-9B3A-4E03-AE5E-1AD6B837422EQ40068432-D7E7E695-8F2C-4654-9C8A-1F146F338B57Q40646055-0BE88077-DB0E-4830-A3B3-6DFB2BBD51A4Q41126011-AC7BD8BB-39E5-4364-AE5C-572AB75107D7
P2860
Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Different structural alteratio ...... ing potency of the erbB-2 gene
@en
type
label
Different structural alteratio ...... ing potency of the erbB-2 gene
@en
prefLabel
Different structural alteratio ...... ing potency of the erbB-2 gene
@en
P2093
P2860
P356
P1476
Different structural alteratio ...... ing potency of the erbB-2 gene
@en
P2093
J H Pierce
P P Di Fiore
S A Aaronson
P2860
P304
P356
10.1128/MCB.8.12.5570
P407
P577
1988-12-01T00:00:00Z